{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T16:53:31Z","timestamp":1715964811208},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1007\/s11864-007-0050-0","type":"journal-article","created":{"date-parts":[[2008,1,2]],"date-time":"2008-01-02T10:59:59Z","timestamp":1199271599000},"page":"393-401","source":"Crossref","is-referenced-by-count":8,"title":["Indications and Efficacy of the Human Papillomavirus Vaccine"],"prefix":"10.1007","volume":"8","author":[{"given":"Amy A.","family":"Hakim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul S.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Wilczynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimhuynh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Billie","family":"Lynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark T.","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,1,3]]},"reference":[{"key":"50_CR1","unstructured":"Centers for Disease Control and Prevention: Quadrivalent Human Papillomavirus Vaccine. Recommendations of the Advisory Committee on Immunization Practices. MMWR 2007, 56(Early Release):1\u201324"},{"key":"50_CR2","doi-asserted-by":"crossref","unstructured":"ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists. Number 61, April 2005. Human Papillomavirus. Obstet Gynecol 2005, 105:905\u2013918","DOI":"10.1097\/00006250-200504000-00056"},{"key":"50_CR3","doi-asserted-by":"crossref","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74\u2013108","DOI":"10.3322\/canjclin.55.2.74"},{"key":"50_CR4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.vaccine.2004.07.046","volume":"23","author":"SR Pagliusi","year":"2004","unstructured":"Pagliusi SR, Teresa Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23:569\u2013578","journal-title":"Vaccine"},{"key":"50_CR5","unstructured":"World health report 2004: Changing history. Statistical annex. World health organization. 2004 [updated 2004; cited]; http:\/\/www\/who.int\/whr\/2004\/en\/index\/htm"},{"key":"50_CR6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","volume":"55","author":"FX Bosch","year":"2002","unstructured":"\u2022\u2022Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus in cervical cancer. J Clin Pathol 2002;55:244\u2013265","journal-title":"J Clin Pathol"},{"key":"50_CR7","doi-asserted-by":"crossref","unstructured":"Schiffman M, Kjaer SK: Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003, 31:14\u201319","DOI":"10.1093\/oxfordjournals.jncimonographs.a003476"},{"key":"50_CR8","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMe078004","volume":"356","author":"S Syrjanen","year":"2007","unstructured":"Syrjanen S. Human Papillomaviruses in head and neck carcinomas. N Engl J Med 2007;356:1993\u20131995","journal-title":"N Engl J Med"},{"key":"50_CR9","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","volume":"347","author":"LA Koutsky","year":"2002","unstructured":"\u2022Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645\u20131651.","journal-title":"N\u2423Engl J Med"},{"key":"50_CR10","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","volume":"348","author":"N Munoz","year":"2003","unstructured":"\u2022\u2022Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518\u2013527.","journal-title":"N Engl J Med"},{"key":"50_CR11","first-page":"101","volume":"10","author":"SK Kjaer","year":"2001","unstructured":"Kjaer SK, Chackerian B, van den Brule AJ, Svare EI, Paull G, Walbomers JM, Schiller JT, Bock JE, Sherman ME, Lowy DR, Meijer CL. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 2001;10:101\u2013106.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"50_CR12","doi-asserted-by":"crossref","unstructured":"Marrazzo JM, Koutsky LA, Kiviat NB, Kuypers JM, Stine K: Papanicolaou test screening and prevalence of genital human papillomavirus among women who have sex with women. Am J Public Health 2001, 91:947\u2013952","DOI":"10.2105\/AJPH.91.6.947"},{"key":"50_CR13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrmicro867","volume":"2","author":"JT Schiller","year":"2004","unstructured":"Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004;2:343\u2013347.","journal-title":"Nat Rev Microbiol"},{"key":"50_CR14","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1086\/315086","volume":"180","author":"EL Franco","year":"1999","unstructured":"Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, Rohan TE. Epidemiology of acquisition and clearance of cervical human Papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415\u20131423.","journal-title":"J Infect Dis"},{"key":"50_CR15","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/aje\/kwg171","volume":"158","author":"M Molano","year":"2003","unstructured":"Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, Meijer CJ, Munoz N, Franceschi S. Determinants of clearance of human Papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol. 2003;158:486\u2013494.","journal-title":"Am J Epidemiol"},{"key":"50_CR16","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/j.1525-1438.2006.00620.x","volume":"16","author":"WA Tjalma","year":"2006","unstructured":"Tjalma WA, van Damme P. Who should be vaccinated against human papillomavirus? Int J Gynecol Cancer 2006;16:1498\u20131499.","journal-title":"Int J Gynecol Cancer"},{"key":"50_CR17","unstructured":"Human Papillomavirus (HPV): http:\/\/www.acog.org\/departments\/govtrel\/FactSheetHPV20070223.pdf"},{"key":"50_CR18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","volume":"54","author":"A Jemal","year":"2004","unstructured":"Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics,2004. CA Cancer J Clin 2004;54:8\u201329.","journal-title":"CA Cancer J Clin"},{"key":"50_CR19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1054\/bjoc.2001.1845","volume":"84","author":"C Clavel","year":"2001","unstructured":"Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P. Human Papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001;84:616\u2013623.","journal-title":"Br J Cancer"},{"key":"50_CR20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/(SICI)1097-0142(19990425)87:2<48::AID-CNCR2>3.0.CO;2-D","volume":"87","author":"ML Hutchinson","year":"1999","unstructured":"Hutchinson ML, Zahniser DJ, Sherman ME, Herrero R, Alfaro M, Bratti MC, Hildesheim A, Lorincz AT, Greenberg MD, Morales J, Schiffman M. Utility of liquid-based cytology for cervical carcinoma screening: results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma. Cancer 1999;87:48\u201355.","journal-title":"Cancer"},{"key":"50_CR21","doi-asserted-by":"crossref","unstructured":"ACOG Committee Opinion No. 344: Human Papillomavirus vaccination. Obstet Gynecol 2006, 108:699\u2013705","DOI":"10.1097\/00006250-200609000-00047"},{"key":"50_CR22","doi-asserted-by":"crossref","unstructured":"ACOG Committee Opinion #300: Cervical cancer screening in adolescents. Obstet Gynecol 2004, 104:885\u2013889","DOI":"10.1097\/00006250-200410000-00047"},{"key":"50_CR23","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1542\/peds.2006-0461","volume":"118","author":"SL Block","year":"2006","unstructured":"Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsague X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF, Jr, Reisinger KS. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human Papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118:2135\u20132145.","journal-title":"Pediatrics"},{"key":"50_CR24","doi-asserted-by":"crossref","unstructured":"Frazer IH, Cox JT, Mayeaux EJ, Jr, Franco EL, Moscicki AB, Palefsky JM, Ferris DG, Ferenczy AS, Villa LL: Advances in prevention of cervical cancer and other human Papillomavirus-related diseases. Pediatr Infect Dis J 2006, 25:S65\u2013S81, quiz S82","DOI":"10.1097\/01.inf.0000196485.86376.46"},{"key":"50_CR25","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","volume":"364","author":"DM Harper","year":"2004","unstructured":"Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human Papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004;364:1757\u20131765.","journal-title":"Lancet"},{"key":"50_CR26","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","volume":"367","author":"DM Harper","year":"2006","unstructured":"\u2022Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4.5\u00a0years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006;367:1247\u20131255.","journal-title":"Lancet"},{"key":"50_CR27","doi-asserted-by":"crossref","unstructured":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915\u20131927.","DOI":"10.1056\/NEJMoa061741"},{"key":"50_CR28","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","volume":"356","author":"SM Garland","year":"2007","unstructured":"\u2022\u2022Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928\u20131943.","journal-title":"N Engl J Med"},{"key":"50_CR29","unstructured":"Food and Drug Administration. Product approval information-licensing action [package insert]. Gardasil (quadrivalent human papillomavirus types 6, 11, 16, and 18). Merck & Co., Whitehouse Station, NJ. Available at http:\/\/www.fda.gov\/cber\/label\/HPVmer060806LB.pdf"},{"key":"50_CR30","unstructured":"Centers for Disease Control and Prevention: General Recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR 2002, 51(No. RR-2):1\u201335"},{"key":"50_CR31","unstructured":"HPV vaccine\u2014ACOG recommendations [cited]; Available from: http:\/\/www.acog.org\/departments\/dept_notice.cfm?recno=7&bulletin=3945"},{"key":"50_CR32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4161\/hv.2.6.3391","volume":"2","author":"K Noakes","year":"2006","unstructured":"Noakes K, Yarwood J, Salisbury D. Parental response to the introduction of a vaccine against human papillomavirus. Hum Vaccin 2006;2:243\u2013248.","journal-title":"Hum Vaccin"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-007-0050-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-007-0050-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-007-0050-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T19:34:18Z","timestamp":1559417658000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-007-0050-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["50"],"URL":"https:\/\/doi.org\/10.1007\/s11864-007-0050-0","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}